These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33483216)

  • 1. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.
    Kohli M; Maschio M; Becker D; Weinstein MC
    Vaccine; 2021 Feb; 39(7):1157-1164. PubMed ID: 33483216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
    Sandmann FG; Davies NG; Vassall A; Edmunds WJ; Jit M;
    Lancet Infect Dis; 2021 Jul; 21(7):962-974. PubMed ID: 33743846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
    Pearson CAB; Bozzani F; Procter SR; Davies NG; Huda M; Jensen HT; Keogh-Brown M; Khalid M; Sweeney S; Torres-Rueda S; ; ; Eggo RM; Vassall A; Jit M
    PLoS Med; 2021 Oct; 18(10):e1003815. PubMed ID: 34606520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States.
    Di Fusco M; Marczell K; Thoburn E; Wiemken TL; Yang J; Yarnoff B
    J Med Econ; 2023; 26(1):509-524. PubMed ID: 36942976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the potential public health and economic impact of different COVID-19 booster dose vaccination strategies with an adapted vaccine in the United Kingdom.
    Harrison C; Butfield R; Yarnoff B; Yang J
    Expert Rev Vaccines; 2024; 23(1):730-739. PubMed ID: 39072472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of medical innovation on the cost-effectiveness of Covid 19-related policies in the United States using a SIR model.
    Atherly AJ; van den Broek-Altenburg EM
    BMC Health Serv Res; 2023 Apr; 23(1):372. PubMed ID: 37072753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States.
    Kohli MA; Maschio M; Joshi K; Lee A; Fust K; Beck E; Van de Velde N; Weinstein MC
    J Med Econ; 2023; 26(1):1532-1545. PubMed ID: 37961887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of COVID-19 vaccination in Poland.
    Orlewska K; Wierzba W; Śliwczynski A
    Arch Med Sci; 2022; 18(4):1021-1030. PubMed ID: 35832692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States.
    Prosser LA; Lavelle TA; Fiore AE; Bridges CB; Reed C; Jain S; Dunham KM; Meltzer MI
    PLoS One; 2011; 6(7):e22308. PubMed ID: 21829456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
    Smith KJ; Wateska AR; Nowalk MP; Raymund M; Nuorti JP; Zimmerman RK
    JAMA; 2012 Feb; 307(8):804-12. PubMed ID: 22357831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population.
    Meijboom MJ; Pouwels KB; Luytjes W; Postma MJ; Hak E
    Vaccine; 2013 Dec; 31(52):6254-60. PubMed ID: 24148573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.
    Lugnér AK; van Boven M; de Vries R; Postma MJ; Wallinga J
    BMJ; 2012 Jul; 345():e4445. PubMed ID: 22791791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the cost-effectiveness of annual COVID-19 booster vaccination in South Korea using a transmission dynamic model.
    Choi W; Shim E
    Front Public Health; 2023; 11():1280412. PubMed ID: 38074736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The global health and economic value of COVID-19 vaccination.
    Sevilla JP; Burnes D; Knee JS; Di Fusco M; Kyaw MH; Yang J; Nguyen JL; Bloom DE
    BMJ Glob Health; 2024 Sep; 9(9):. PubMed ID: 39244220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults.
    Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Zimmerman RK
    J Am Geriatr Soc; 2016 Oct; 64(10):2126-2131. PubMed ID: 27709600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the impacts of COVID-19 vaccination programme's timing and speed on health benefits, cost-effectiveness, and relative affordability in 27 African countries.
    Liu Y; Procter SR; Pearson CAB; Montero AM; Torres-Rueda S; Asfaw E; Uzochukwu B; Drake T; Bergren E; Eggo RM; Ruiz F; Ndembi N; Nonvignon J; Jit M; Vassall A
    BMC Med; 2023 Mar; 21(1):85. PubMed ID: 36882868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cost-Effectiveness of a COVID-19 Vaccine in a Danish Context.
    Debrabant K; Grønbæk L; Kronborg C
    Clin Drug Investig; 2021 Nov; 41(11):975-988. PubMed ID: 34623627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.